STOCK TITAN
  1. Home
  2. News
  3. ICCM

Icecure Medical Ltd - ICCM STOCK NEWS

Welcome to our dedicated news page for Icecure Medical (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icecure Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icecure Medical's position in the market.

News
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
Rhea-AI Summary
IceCure Medical reports final ICE3 breast cancer cryoablation trial results with 100% patient and physician satisfaction and a 96.3% recurrence-free rate. The data submitted to the FDA seeks marketing authorization to treat early-stage breast cancer. The study shows similar outcomes to lumpectomy, the current standard of care, with no significant device-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
none
-
News
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
Rhea-AI Summary
IceCure Medical (ICCM) reports a 26% increase in product sales for the twelve months ended December 31, 2023, with key financial highlights including a 26% rise in global product sales, 24% growth in U.S. sales, and cash and cash equivalents of $11.1 million. The company raised $3 million in the first quarter of 2024. IceCure's CEO, Eyal Shamir, highlights the completion of the ICE3 breast cancer study, positive results, and FDA submission plans. Recent highlights include regulatory approvals, global rollout momentum, independent studies supporting ProSense® in various indications, IP portfolio growth, and financial results showing a minor revenue increase and decreased net loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
earnings
-
News
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
Rhea-AI Summary
IceCure Medical files 510(k) submission with the FDA for its next-generation single probe cryoablation system, XSense™ System, and cryoprobes. The submission aims to expand the indications for minimally invasive cryoablation applications, building on the success of the ProSense® System. IceCure continues to lead in liquid nitrogen-based cryoablation technologies, focusing on innovation and market expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
none
News
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Rhea-AI Summary
IceCure Medical will release financial and operational results for the twelve months ended December 31, 2023, discussing them on a conference call on April 3, 2024. The company's executives will provide insights into the commercial strategy for the ProSense® System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences earnings
-
News
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Rhea-AI Summary
IceCure Medical (ICCM) announces positive topline results from the largest cryoablation study in the U.S. for early-stage breast cancer treatment. The ICE3 study showed a 96.39% local recurrence-free rate with no device-related adverse events. ProSense® is positioned as a safe and effective alternative to lumpectomy. IceCure plans to submit the full dataset to the FDA in April for marketing authorization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
clinical trial
-
News
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
Rhea-AI Summary
IceCure Medical Ltd. (ICCM) receives a Notice of Allowance from the Japan Patent Office for its 'Cryogen Flow Control' patent, enhancing cryoablation procedures. The patent will be effective until 2042, with pending approvals in the EU, the U.S., and other major markets. Cryogenic flow control optimizes temperature regulation for improved treatment efficacy and tissue safety, potentially expanding cryoablation applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) announces CEO's presentation at Oppenheimer Healthcare MedTech & Services Conference. The presentation will cover the ICE3 breast cancer trial, De Novo Classification Request with the FDA, global commercial reach of ProSense®, and independent research on cryoablation efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
Rhea-AI Summary
IceCure Medical Ltd. (ICCM) announces positive results from an independent study on cryoablation technology for endometriosis treatment. The study showed the disappearance of hemorrhagic signals, development of necrotic changes, and significant pain reduction in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
News
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) announces the successful feature of ProSense® at the BRIIT conference in India, highlighting its innovative cryoablation technology for breast tumors. Dr. Rupa Renganathan and Dr. Hania Bednarski shared their expertise in cryoablation procedures, showcasing ProSense®'s efficacy and regulatory approval in India.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
Rhea-AI Summary
IceCure Medical Ltd. announces groundbreaking results from an independent study on breast cancer treatment using its ProSense® System, reporting a median tumor reduction of 100% at 6 and 12 months post-cryoablation. The study conducted on inoperable women aged 60-92 showcases the effectiveness of cryoablation technology in destroying tumors non-invasively, offering new hope for patients who cannot undergo surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
Stock ICCM logo
Icecure Medical Ltd

Nasdaq:ICCM

ICCM Rankings

#4664 Ranked by Market Cap
#3940 Ranked by Stock Gains
N/A Ranked by Dividends

ICCM Stock Data

57.16M
18.90M
59.3%
0.66%
0.77%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
Caesarea